Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Royal Dutch Shell plc stock logo
RDS-A
Royal Dutch Shell
$51.04
$46.10
$0.00
$0.00
N/AN/AN/AN/A
Rio Tinto Group stock logo
RIO
Rio Tinto Group
$67.89
+0.6%
$64.94
$58.27
$75.09
$85.03B0.682.94 million shs507,001 shs
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$13.99
+0.1%
$13.57
$7.09
$14.47
$15.68B1.0410.42 million shs2.49 million shs
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Royal Dutch Shell plc stock logo
RDS-A
Royal Dutch Shell
0.00%0.00%0.00%0.00%0.00%
Rio Tinto Group stock logo
RIO
Rio Tinto Group
-0.50%-0.96%+5.17%-3.77%+8.64%
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
-0.36%+7.46%+0.54%+12.24%+58.86%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Royal Dutch Shell plc stock logo
RDS-A
Royal Dutch Shell
N/AN/AN/AN/AN/AN/AN/AN/A
Rio Tinto Group stock logo
RIO
Rio Tinto Group
1.2136 of 5 stars
1.44.02.50.03.30.00.6
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
0.8702 of 5 stars
1.43.00.00.02.61.71.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Royal Dutch Shell plc stock logo
RDS-A
Royal Dutch Shell
N/AN/AN/AN/A
Rio Tinto Group stock logo
RIO
Rio Tinto Group
2.80
Moderate Buy$72.006.05% Upside
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
2.70
Moderate Buy$13.78-1.52% Downside

Current Analyst Ratings

Latest TEVA, RIO, and RDS-A Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/8/2024
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderweight ➝ Neutral$14.00
3/5/2024
Rio Tinto Group stock logo
RIO
Rio Tinto Group
Liberum Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
2/12/2024
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight$12.00 ➝ $19.00
2/5/2024
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$10.00 ➝ $11.00
2/5/2024
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$15.00 ➝ $17.00
(Data available from 5/2/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Royal Dutch Shell plc stock logo
RDS-A
Royal Dutch Shell
N/AN/AN/AN/AN/AN/A
Rio Tinto Group stock logo
RIO
Rio Tinto Group
$54.04B1.57$13.66 per share4.97$45.03 per share1.51
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$15.85B0.99$3.51 per share3.99$7.25 per share1.93

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Royal Dutch Shell plc stock logo
RDS-A
Royal Dutch Shell
N/AN/A0.00N/AN/AN/AN/AN/A
Rio Tinto Group stock logo
RIO
Rio Tinto Group
$10.06BN/A0.009.203.10N/AN/AN/AN/A
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
-$559M-$0.47N/A5.571.68-3.33%34.90%6.48%5/8/2024 (Confirmed)

Latest TEVA, RIO, and RDS-A Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2024N/A
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$0.49N/A-$0.49N/AN/AN/A  

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Royal Dutch Shell plc stock logo
RDS-A
Royal Dutch Shell
N/AN/AN/AN/AN/A
Rio Tinto Group stock logo
RIO
Rio Tinto Group
$5.157.59%+1.36%N/A1 Years
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
N/AN/AN/AN/AN/A

Latest TEVA, RIO, and RDS-A Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/21/2024
Rio Tinto Group stock logo
RIO
Rio Tinto Group
semi-annual$2.586.6%3/7/20243/8/20244/18/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Royal Dutch Shell plc stock logo
RDS-A
Royal Dutch Shell
N/AN/AN/A
Rio Tinto Group stock logo
RIO
Rio Tinto Group
0.23
1.69
1.17
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
2.23
1.02
0.69

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Royal Dutch Shell plc stock logo
RDS-A
Royal Dutch Shell
N/A
Rio Tinto Group stock logo
RIO
Rio Tinto Group
19.33%
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
54.05%

Insider Ownership

CompanyInsider Ownership
Royal Dutch Shell plc stock logo
RDS-A
Royal Dutch Shell
N/A
Rio Tinto Group stock logo
RIO
Rio Tinto Group
N/A
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
0.55%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Royal Dutch Shell plc stock logo
RDS-A
Royal Dutch Shell
87,000N/AN/AN/A
Rio Tinto Group stock logo
RIO
Rio Tinto Group
57,0001.25 billionN/AOptionable
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
37,8511.12 billion1.11 billionOptionable

TEVA, RIO, and RDS-A Headlines

SourceHeadline
Tevas 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious TargetsTeva's 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets
businesswire.com - May 2 at 8:30 AM
Van ECK Associates Corp Has $20.28 Million Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)Van ECK Associates Corp Has $20.28 Million Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)
marketbeat.com - May 1 at 7:32 AM
Traders Buy Large Volume of Teva Pharmaceutical Industries Call Options (NYSE:TEVA)Traders Buy Large Volume of Teva Pharmaceutical Industries Call Options (NYSE:TEVA)
americanbankingnews.com - May 1 at 4:10 AM
Teva Pharmaceutical Industries (TEVA) Scheduled to Post Earnings on WednesdayTeva Pharmaceutical Industries (TEVA) Scheduled to Post Earnings on Wednesday
americanbankingnews.com - May 1 at 2:52 AM
FTC Warns ‘Junk Patents’ Could Make Drugs Like Ozempic Pricier—Here’s HowFTC Warns ‘Junk Patents’ Could Make Drugs Like Ozempic Pricier—Here’s How
msn.com - April 30 at 5:32 PM
Investors Purchase Large Volume of Call Options on Teva Pharmaceutical Industries (NYSE:TEVA)Investors Purchase Large Volume of Call Options on Teva Pharmaceutical Industries (NYSE:TEVA)
marketbeat.com - April 30 at 2:43 PM
Tue: Strong gains today but TA 35 Index down 3% in AprilTue: Strong gains today but TA 35 Index down 3% in April
en.globes.co.il - April 30 at 12:32 PM
Alvotech to produce Humira biosimilar for Cignas QuallentAlvotech to produce Humira biosimilar for Cigna's Quallent
msn.com - April 30 at 12:32 PM
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First ...U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First ...
eagletribune.com - April 30 at 7:31 AM
Alvotech To Manufacture Its High-concentration Interchangeable Biosimilar To Humira For QuallentAlvotech To Manufacture Its High-concentration Interchangeable Biosimilar To Humira For Quallent
markets.businessinsider.com - April 30 at 7:31 AM
abrdn plc Acquires 449,053 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)abrdn plc Acquires 449,053 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)
marketbeat.com - April 28 at 5:29 AM
The Sound Shore Fund Q1 2024 Letter To ShareholdersThe Sound Shore Fund Q1 2024 Letter To Shareholders
seekingalpha.com - April 24 at 10:36 AM
Private Management Group Inc. Sells 98,730 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)Private Management Group Inc. Sells 98,730 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)
marketbeat.com - April 23 at 10:25 PM
Number of Cape pharmacies ditch Israeli medicines to become ‘Apartheid Free Zone’Number of Cape pharmacies ditch Israeli medicines to become ‘Apartheid Free Zone’
msn.com - April 19 at 7:21 AM
Alvotech, Teva signs deal to expand access for Humira biosimilar in U.S.Alvotech, Teva signs deal to expand access for Humira biosimilar in U.S.
msn.com - April 19 at 7:21 AM
3 Generic Drug Stocks to Watch Amid Challenging Market Prospects3 Generic Drug Stocks to Watch Amid Challenging Market Prospects
zacks.com - April 18 at 12:16 PM
Teva, Alvotech Secure FDA Approval for Stelara Biosimilar with Early 2025 LaunchTeva, Alvotech Secure FDA Approval for Stelara Biosimilar with Early 2025 Launch
biospace.com - April 18 at 10:05 AM
Zacks Research Analysts Boost Earnings Estimates for Teva Pharmaceutical Industries Limited (NYSE:TEVA)Zacks Research Analysts Boost Earnings Estimates for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
marketbeat.com - April 18 at 6:31 AM
USFDA approves Selarsdi injection for subcutaneous use to treat severe plaque psoriasis, active psoriatic arthritis: Alvotech, TevaUSFDA approves Selarsdi injection for subcutaneous use to treat severe plaque psoriasis, active psoriatic arthritis: Alvotech, Teva
medicaldialogues.in - April 17 at 5:34 PM
Migdal Insurance & Financial Holdings Ltd. Acquires 1,860,000 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)Migdal Insurance & Financial Holdings Ltd. Acquires 1,860,000 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)
marketbeat.com - April 17 at 2:37 PM
Alvotech and Teva win FDA approval of Stelara copyAlvotech and Teva win FDA approval of Stelara copy
thepharmaletter.com - April 17 at 12:31 PM
Alvotech and Teva gain FDA approval of SELARSDI for psoriasisAlvotech and Teva gain FDA approval of SELARSDI for psoriasis
pharmaceutical-technology.com - April 17 at 7:30 AM
Teva CEO Francis becomes highest paid TASE co execTeva CEO Francis becomes highest paid TASE co exec
en.globes.co.il - April 17 at 7:30 AM
Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) TabletsTeva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets
finance.yahoo.com - April 16 at 8:42 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Royal Dutch Shell logo

Royal Dutch Shell

NYSE:RDS-A
Royal Dutch Shell plc operates as an energy and petrochemical company worldwide. The company operates through Integrated Gas, Upstream, Oil Products, Chemicals segments. It explores for and extracts crude oil, natural gas, and natural gas liquids; markets and transports oil and gas; produces gas-to-liquids fuels and other products; and operates upstream and midstream infrastructure necessary to deliver gas to market. The company also markets and trades natural gas, liquefied natural gas (LNG), crude oil, electricity, carbon-emission rights; and markets and sells LNG as a fuel for heavy-duty vehicles and marine vessels. In addition, it trades in and refines crude oil and other feed stocks, such as gasoline, diesel, heating oil, aviation fuel, marine fuel, biofuel, lubricants, bitumen, and sulphur; produces and sells petrochemicals for industrial use; and manages oil sands activities. Further, the company produces base chemicals comprising ethylene, propylene, and aromatics, as well as intermediate chemicals, such as styrene monomer, propylene oxide, solvents, detergent alcohols, ethylene oxide, and ethylene glycol. Royal Dutch Shell plc was founded in 1907 and is headquartered in The Hague, the Netherlands.
Rio Tinto Group logo

Rio Tinto Group

NYSE:RIO
Rio Tinto Group engages in exploring, mining, and processing mineral resources worldwide. The company operates through Iron Ore, Aluminium, Copper, and Minerals Segments. The Iron Ore segment engages in the iron ore mining, and salt and gypsum production in Western Australia. The Aluminum segment is involved in bauxite mining; alumina refining; and aluminium smelting. The Copper segment engages in mining and refining of copper, gold, silver, molybdenum, and other by-products and exploration activities. The Minerals segment is involved in mining and processing of borates, titanium dioxide feedstock, and iron concentrate and pellets; diamond mining, sorting, and marketing; and development projects for battery materials, such as lithium. It also owns and operates open pit and underground mines; and refineries, smelters, processing plants and power, and shipping facilities. Rio Tinto Group was founded in 1873 and is headquartered in London, the United Kingdom.
Teva Pharmaceutical Industries logo

Teva Pharmaceutical Industries

NYSE:TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.